Guillain-Barré syndrome laboratory tests: Difference between revisions
Jump to navigation
Jump to search
| (30 intermediate revisions by 8 users not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | |||
{{Guillain-Barré syndrome}} | {{Guillain-Barré syndrome}} | ||
{{CMG}}; {{AE}} {{Fs}} | |||
{{CMG}}; | |||
==Overview== | ==Overview== | ||
Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include: Elevated [[CSF]] [[protein]] level, normal [[CSF]] [[WBC]] count, normal [[CSF]] cell count (in some cases there is mildly elevated cell count) and serum [[Immunoglobulin G|IgG antibody]] to GQ1b in [[Miller Fisher syndrome]]. | |||
==Laboratory | ==Laboratory Findings== | ||
* Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include:<ref name="pmid37076309">{{cite journal| author=Al-Hakem H, Doets AY, Stino AM, Zivkovic SA, Andersen H, Willison HJ | display-authors=etal| title=CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome. | journal=Neurology | year= 2023 | volume= 100 | issue= 23 | pages= e2386-e2397 | pmid=37076309 | doi=10.1212/WNL.0000000000207282 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=37076309 }} </ref><ref name="pmid22694000">{{cite journal |vauthors=Yuki N, Hartung HP |title=Guillain-Barré syndrome |journal=N. Engl. J. Med. |volume=366 |issue=24 |pages=2294–304 |date=June 2012 |pmid=22694000 |doi=10.1056/NEJMra1114525 |url=}}</ref><ref name="pmid14975602">{{cite journal |vauthors=Nishimoto Y, Odaka M, Hirata K, Yuki N |title=Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination |journal=J. Neuroimmunol. |volume=148 |issue=1-2 |pages=200–5 |date=March 2004 |pmid=14975602 |doi=10.1016/j.jneuroim.2003.11.017 |url=}}</ref><ref name="pmid24163275">{{cite journal |vauthors=Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC |title=Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria |journal=Brain |volume=137 |issue=Pt 1 |pages=33–43 |date=January 2014 |pmid=24163275 |doi=10.1093/brain/awt285 |url=}}</ref><ref name="pmid8413947">{{cite journal |vauthors=Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I |title=Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies |journal=Neurology |volume=43 |issue=10 |pages=1911–7 |date=October 1993 |pmid=8413947 |doi= |url=}}</ref> | |||
** Elevated [[CSF]] [[protein]] level. | |||
** Normal [[CSF]] [[WBC]] count. | |||
* | ** Normal [[CSF]] cell count (in some cases there is mildly elevated cell count) | ||
** Serum [[Immunoglobulin G|IgG antibody]] to GQ1b in [[Miller Fisher syndrome]]. | |||
* | |||
* [[ | |||
* | |||
* | |||
* | |||
==References== | ==References== | ||
| Line 29: | Line 18: | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
[[Category:Autoimmune diseases]] | [[Category:Autoimmune diseases]] | ||
[[Category:Neurological disorders]] | [[Category:Neurological disorders]] | ||
[[Category:Neurology]] | [[Category:Neurology]] | ||
[[Category:Immunology]] | [[Category:Immunology]] | ||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Emergency medicine]] | [[Category:Emergency medicine]] | ||
Latest revision as of 01:36, 7 June 2023
|
Guillain-Barré syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Guillain-Barré syndrome laboratory tests On the Web |
|
American Roentgen Ray Society Images of Guillain-Barré syndrome laboratory tests |
|
Risk calculators and risk factors for Guillain-Barré syndrome laboratory tests |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include: Elevated CSF protein level, normal CSF WBC count, normal CSF cell count (in some cases there is mildly elevated cell count) and serum IgG antibody to GQ1b in Miller Fisher syndrome.
Laboratory Findings
- Laboratory findings consistent with the diagnosis of Guillain Barre syndrome include:[1][2][3][4][5]
- Elevated CSF protein level.
- Normal CSF WBC count.
- Normal CSF cell count (in some cases there is mildly elevated cell count)
- Serum IgG antibody to GQ1b in Miller Fisher syndrome.
References
- ↑ Al-Hakem H, Doets AY, Stino AM, Zivkovic SA, Andersen H, Willison HJ; et al. (2023). "CSF Findings in Relation to Clinical Characteristics, Subtype, and Disease Course in Patients With Guillain-Barré Syndrome". Neurology. 100 (23): e2386–e2397. doi:10.1212/WNL.0000000000207282. PMID 37076309 Check
|pmid=value (help). - ↑ Yuki N, Hartung HP (June 2012). "Guillain-Barré syndrome". N. Engl. J. Med. 366 (24): 2294–304. doi:10.1056/NEJMra1114525. PMID 22694000.
- ↑ Nishimoto Y, Odaka M, Hirata K, Yuki N (March 2004). "Usefulness of anti-GQ1b IgG antibody testing in Fisher syndrome compared with cerebrospinal fluid examination". J. Neuroimmunol. 148 (1–2): 200–5. doi:10.1016/j.jneuroim.2003.11.017. PMID 14975602.
- ↑ Fokke C, van den Berg B, Drenthen J, Walgaard C, van Doorn PA, Jacobs BC (January 2014). "Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria". Brain. 137 (Pt 1): 33–43. doi:10.1093/brain/awt285. PMID 24163275.
- ↑ Chiba A, Kusunoki S, Obata H, Machinami R, Kanazawa I (October 1993). "Serum anti-GQ1b IgG antibody is associated with ophthalmoplegia in Miller Fisher syndrome and Guillain-Barré syndrome: clinical and immunohistochemical studies". Neurology. 43 (10): 1911–7. PMID 8413947.